Clinical Characteristics of COVID-19 Patients Receiving ECMO Treatment for Severe Acute Respiratory Distress Syndrome

Xin Li

doi:10.26717/bjstr.2020.32.005223

Abstract

Jie Li1#, Chengbin Zhou2#, Lianghai Li3#, Cong Mai4, Junmin Wen5, Haigang Zhang6, Jinxiu Li7, Ping Jin3, Renqiang Yang4, Chuangqiang Lin4,8, Zhaojun Liu1, Xia Zou1, Fei Zhong1, Ding Ding1, Weifeng Li4, Bei Hu4* and Xin Li4* Author Affiliations 1Global Health Research Center, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China 2Department of Cardiovascular Surgery, Guangdong Provincial Key Laboratory of South China Structural Heart Disease, Guangdong Cardiovascular Institute, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China 3Department of Intensive Care Unit (ICU), Jingzhou Central Hospital; The Second Clinical Medical College, Yangtze University, Jingzhou, China 4Department of Emergency and Critical Care Medicine, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China 5Fuwai Hospital, Chinese Academy of Medical Sciences, Shenzhen, China 6Department of critical care medicine, Huazhong University of Science and Technology Union Shenzhen Hospital, Shenzhen, China 7The department of critical care medicine, Shenzhen Third People’s Hospital, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen, China 8Shantou University Medical College, Shantou, China #These authors contributed equally Received: November 16, 2020| Published: December 01, 2020 Corresponding author: Xin Li and Bei Hu, Department of Emergency, Department of Emergency and Critical Care Medicine, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China DOI: 10.26717/BJSTR.2020.32.005223

Highlights

The novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global pandemic at the beginning of 2020 and affected almost all of the human beings on this planet directly or indirectly
Our results demonstrated that ABO blood group and patterns of changes of Partial Pressure Of Oxygen (Pao2)/Fractional Of Inspired Oxygen (Fio2), lactic acid, lymphocyte count, neutrophil-to-lymphocyte ratio (NLR), and C-reactive protein (CRP) around Extracorporeal Membrane Oxygenation (ECMO) initiation (±48h) may be related to the outcome of ECMO therapy in COVID-19 patients
Our findings demonstrated that ABO blood group and changes of Pao2/Fio2, lactic acid, NLR, and CRP around ECMO initiation may be related to prognosis of ECMO support among COVID-19 patients with acute respiratory distress syndrome (ARDS)

Summary

Introduction

The novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global pandemic at the beginning of 2020 and affected almost all of the human beings on this planet directly or indirectly. A report including approximately 72,314 cases from the Chinese Center for Disease Control and Prevention demonstrated that over 5% of COVID-19 patients developed severe pneumonia and had a high risk of acute respiratory distress syndrome (ARDS) [1,3]. A recent study showed that only half of the COVID-19 patients receiving ECMO support were survival [4]. We aimed to summary the factors related to the outcomes of COVID-19 patients receiving ECMO therapy, which may help the health workers in intensive care unit (ICU) make decisions on choosing the most appropriate treatment for a particular COVID-19 patient with ARDS. Extracorporeal Membrane Oxygenation (ECMO) is considered as the last rescue treatment for patients with acute respiratory distress syndrome (ARDS)

Objectives

Results

Discussion

Conclusion